Journal of Pathology and Translational Medicine

Original Article

MicroRNA-374a Expression as a Prognostic Biomarker in Lung Adenocarcinoma: Yeseul Kim, Jongmin Sim, Hyunsung Kim, Seong Sik Bang, Seungyun Jee, Sungeon Park, Kiseok Jang; J Pathol Transl Med. 2019;53(6):354-360. Published online October 24, 2019; DOI: https://doi.org/10.4132/jptm.2019.10.01

4,529 View
124 Download
4 Web of Science
4 Crossref

Background
Lung cancer is the most common cause of cancer-related death, and adenocarcinoma is the most common histologic subtype. MicroRNA is a small non-coding RNA that inhibits multiple target gene expression at the post-transcriptional level and is commonly dysregulated in malignant tumors. The purpose of this study was to analyze the expression of microRNA-374a (miR-374a) in lung adenocarcinoma and correlate its expression with various clinicopathological characteristics.
Methods
The expression level of miR-374a was measured in 111 formalin-fixed paraffin-embedded lung adenocarcinoma tissues using reverse transcription-quantitative polymerase chain reaction assays. The correlation between miR-374a expression and clinicopathological parameters, including clinical outcome, was further analyzed.
Results
High miR-374 expression was correlated with advanced pT category (chi-square test, p=.004) and pleural invasion (chi-square test, p=.034). Survival analysis revealed that patients with high miR-374a expression had significantly shorter disease-free survival relative to those with low miR-374a expression (log-rank test, p=.032).
Conclusions
miR-374a expression may serve as a potential prognostic biomarker for predicting recurrence in early stage lung adenocarcinoma after curative surgery.

Citations

Citations to this article as recorded by

Cell-free plasma miRNAs analysis for low invasive lung cancer diagnostics
M. Yu. Konoshenko, P. P. Laktionov, Yu. A. Lancuhaj, S. V. Pak, S. E. Krasilnikov, O. E. Bryzgunova
Advances in Molecular Oncology.2023; 10(2): 78. CrossRef
MicroRNA‑mediated regulation in lung adenocarcinoma: Signaling pathways and potential therapeutic implications (Review)
Jiye Liu, Fei Zhang, Jiahe Wang, Yibing Wang
Oncology Reports.2023;[Epub] CrossRef
Dysregulation of miR-374a is involved in the progression of diabetic retinopathy and regulates the proliferation and migration of retinal microvascular endothelial cells
Zhanhong Wang, Xiao Zhang, Yanjun Wang, Dailing Xiao
Clinical and Experimental Optometry.2022; 105(3): 287. CrossRef
MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer
Jong-Lyul Park, Seon-Kyu Kim, Sora Jeon, Chan-Kwon Jung, Yong-Sung Kim
Cancers.2021; 13(4): 632. CrossRef

Case Study

Recurrent Indeterminate Dendritic Cell Tumor of the Skin: Jin Woo Joo, Taek Chung, Yoon Ah Cho, Sang Kyum Kim; J Pathol Transl Med. 2018;52(4):243-247. Published online April 5, 2018; DOI: https://doi.org/10.4132/jptm.2018.03.27

5,837 View
97 Download
2 Web of Science
1 Crossref

Abstract PDF

Indeterminate dendritic cell tumor (IDCT) is a dendritic cell tumor that displays histologic features similar to those of Langerhans cells. The origin of the indeterminate cells may represent precursors of Langerhans cells or skin dendritic cells. IDCT is extremely rare, and tumor progression and predictive factors are not well known. Here, we report a case of a 61-year-old man who presented with a papule on his back and was finally diagnosed with IDCT based on histology and immunohistochemistry. The tumor recurred three months after surgical excision.

Citations

Citations to this article as recorded by

Indeterminate cell histiocytosis: A systematic review of the literature with a comprehensive revision of clinical, histopathological, and molecular features
Simone Zanella, Emilio Berti, Arturo Bonometti
Journal of the European Academy of Dermatology and Venereology.2023; 37(8): 1559. CrossRef

Original Article

Clinicopathological Study of 18 Cases of Inflammatory Myofibroblastic Tumors with Reference to ALK-1 Expression: 5-Year Experience in a Tertiary Care Center: Ramesh Babu Telugu, Anne Jennifer Prabhu, Nobin Babu Kalappurayil, John Mathai, Birla Roy Gnanamuthu, Marie Therese Manipadam; J Pathol Transl Med. 2017;51(3):255-263. Published online April 17, 2017; DOI: https://doi.org/10.4132/jptm.2017.01.12

10,879 View
377 Download
19 Web of Science
23 Crossref

Abstract PDF

Background
Inflammatory myofibroblastic tumor is a histopathologically distinctive neoplasm of children and young adults. According to World Health Organization (WHO) classification, inflammatory myofibroblastic tumor is an intermediate-grade tumor, with potential for recurrence and rare metastasis. There are no definite histopathologic, molecular, or cytogenetic features to predict malignant transformation, recurrence, or metastasis.
Methods
A 5-year retrospective study of histopathologically diagnosed inflammatory myofibroblastic tumors of various anatomic sites was conducted to correlate anaplastic lymphoma kinase-1 (ALK-1) expression with histological atypia, multicentric origin of tumor, recurrence, and metastasis. Clinical details of all the cases were noted from the clinical work station. Immunohistochemical stains for ALK-1 and other antibodies were performed. Statistical analysis was done using Fisher exact test.
Results
A total of 18 cases of inflammatory myofibroblastic tumors were found during the study period, of which 14 were classical. The female-male ratio was 1:1 and the mean age was 23.8 years. Histologically atypical (four cases) and multifocal tumors (three cases, multicentric in origin) were noted. Recurrence was noted in 30% of ALK-1 positive and 37.5% of ALK-1 negative cases, whereas metastasis to the lung, liver, and pelvic bone was noted in the ALK-1 positive group only.
Conclusions
Overall, ALK-1 protein was expressed in 55.6% of inflammatory myofibroblastic tumors. There was no statistically significant correlation between ALK-1 expression, tumor type, recurrence and metastasis. However, ALK-1 immunohistochemistry is a useful diagnostic aid in the appropriate clinical and histomorphologic context.

Citations

Citations to this article as recorded by

Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
Mengmeng Li, Ruyue Xing, Jiuyan Huang, Chao Shi, Chunhua Wei, Huijuan Wang
Frontiers in Oncology.2023;[Epub] CrossRef
Inflammatory Myofibroblastic Tumour of the Sinonasal Tract with Orbital and Intracranial Extensions Simulating a Malignancy: A Case Report and Review of Literature
Gaveshani Mantri, Subhalaxmi Rautray, Rahul Mohanty, Vinushree Karakkandy
Indian Journal of Otolaryngology and Head & Neck Surgery.2022; 74(S2): 1668. CrossRef
Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents
Aurore Pire, Daniel Orbach, Louise Galmiche, Dominique Berrebi, Sabine Irtan, Sabah Boudjemaa, Hervé J. Brisse, Laureline Berteloot, Salma Moalla, Charlotte Mussini, Pascale Philippe‐Chomette, Bogdana Tilea, Gaelle Pierron, Florent Guerin, Véronique Minar
Pediatric Blood & Cancer.2022;[Epub] CrossRef
Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring EML4-ALK Fusion Gene: Study of Two Typical Cases and Review of Literature
Qianqian Han, Xin He, Lijuan Cui, Yan Qiu, Yuli Li, Huijiao Chen, Hongying Zhang
Frontiers in Medicine.2022;[Epub] CrossRef
Inflammatory myofibroblastic tumor: A multi‐institutional study from the Pediatric Surgical Oncology Research Collaborative
Barrie S. Rich, Joanna Fishbein, Timothy Lautz, Nathan S. Rubalcava, Tanvi Kartal, Erika Newman, Pei En Wok, Rodrigo L. P. Romao, Richard Whitlock, Bindi Naik‐Mathuria, Stephanie F. Polites, Katrine Løfberg, Danny Lascano, Eugene Kim, Jacob Davidson, Andr
International Journal of Cancer.2022; 151(7): 1059. CrossRef
Child inflammatory myofibroblastic tumor of the kidney misdiagnosed as Wilms' tumor: case report
Yu-Feng Bai, Jing-Zhong Liu, Li-Na Yue, Li Chen, Sui-Yi Liu, Rui Liu
Radiology Case Reports.2022; 17(12): 4920. CrossRef
A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement
Vasyl Nesteryuk, Omar Hamdani, Raymond Gong, Nava Almog, Brian M. Alexander, Steffan Soosman, Ken Yoneda, Siraj M. Ali, Alexander D. Borowsky, Jonathan W. Riess
Clinical Lung Cancer.2022; 23(8): e550. CrossRef
An extremely rare case of malignant jejunal mesenteric inflammatory myofibroblastic tumor in a 61-year-old male patient: A case report and literature review
Hamdi Al Shenawi, Salamah A. Al-Shaibani, Suhair K. Al Saad, Fedaa Al-Sindi, Khalid Al-Sindi, Noor Al Shenawi, Yahya Naguib, Rami Yaghan
Frontiers in Medicine.2022;[Epub] CrossRef
Primary inflammatory myofibroblastic tumor of stomach—report of a very rare case
Ranendra Hajong, Kewithinwangbo Newme, Donkupar Khongwar
Journal of Family Medicine and Primary Care.2021; 10(1): 552. CrossRef
Complicated course of biliary inflammatory myofibroblastic tumor mimicking hilar cholangiocarcinoma: A case report and literature review
Sandra Strainiene, Kotryna Sedleckaite, Juozas Jarasunas, Ilona Savlan, Juozas Stanaitis, Ieva Stundiene, Tomas Strainys, Valentina Liakina, Jonas Valantinas
World Journal of Clinical Cases.2021; 9(21): 6155. CrossRef
Epithelioid Inflammatory Myofibroblastic Sarcoma Presenting as Gastrointestinal Bleed: Case Report and Literature Review
Alexandra Giannaki, Dimitrios Doganis, Panagiota Giamarelou, Anastasia Konidari
JPGN Reports.2021; 2(1): e019. CrossRef
Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement
Camila B. Xavier, Felipe S.N.A. Canedo, Fabíola A.S. Lima, Raíssa R. Melo, Luiz Guilherme C.A. Lima, José Flávio G. Marin, Ciro E. Souza, Olavo Feher
Current Problems in Cancer: Case Reports.2021; 4: 100117. CrossRef
Urinary Bladder Inflammatory Myofibroblastic Tumor With Mutated TP53 and PPFIBP1-ALK Gene Fusion
Andreia N. Barbieri, Christopher T. Tallman, Raj Satkunasivam, Joseph Annunziata, Jessica S. Thomas, Randall J. Olsen, Steven S. Shen, Michael J. Thrall, Mary R. Schwartz
AJSP: Reviews and Reports.2021; 26(1): 45. CrossRef
Therapeutic options in inoperable ROS1-rearranged inflammatory myofibroblastic tumor of the tongue in a child: a case report and literature review
Malgorzata Styczewska, Agastya Patel, Joanna Jaskulowska, Jan Godzinski, Dominik Swieton, Bartosz Wasag, Juliea Dass, Ewa Bien, Malgorzata A. Krawczyk
Anti-Cancer Drugs.2021; 32(10): 1111. CrossRef
Non-squamous cell carcinoma diseases of the larynx: clinical and imaging findings
Serap Doğan, Alperen Vural, Güven Kahriman, Hakan İmamoğlu, Ümmühan Abdülrezzak, Mustafa Öztürk
Brazilian Journal of Otorhinolaryngology.2020; 86(4): 468. CrossRef
Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases
Xiaoyan Si, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Yan You, Li Zhang
Thoracic Cancer.2020; 11(8): 2339. CrossRef
Rare presentation of inflammatory myofibroblastic tumor in the kidney
Hiba Abduljawad, Ahmet Aslan, Khalifa Aldoseri, Erdem Yilmaz, Wael Ibrahim
Radiology Case Reports.2020; 15(8): 1266. CrossRef
Histopathological landscape of rare oesophageal neoplasms
Gianluca Businello, Carlo Alberto Dal Pozzo, Marta Sbaraglia, Luca Mastracci, Massimo Milione, Luca Saragoni, Federica Grillo, Paola Parente, Andrea Remo, Elena Bellan, Rocco Cappellesso, Gianmaria Pennelli, Mauro Michelotto, Matteo Fassan
World Journal of Gastroenterology.2020; 26(27): 3865. CrossRef
Laryngeal Inflammatory Myofibroblastic Tumor : Case Series and Literature Review
Ki-Ik Park, Sung-hoon Kim, In-Suh Park, Ji Won Kim
Journal of The Korean Society of Laryngology, Phoniatrics and Logopedics.2019; 30(1): 57. CrossRef
Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib
Qiuxia Liu, Jianguo Wei, Xizhong Liu, Jianfang Wang
Medicine.2019; 98(52): e18414. CrossRef
Inflammatory myofibroblastic tumor
Veronika Marcináková, Hana Dittrichová, Karel Franěk, Pavel Hanek
Urologie pro praxi.2019; 20(1): 40. CrossRef
Ureteral inflammatory myofibroblastic tumor
Faping Li, Hui Guo, Heping Qiu, Yuchuan Hou
Medicine.2018; 97(46): e13177. CrossRef
Pulmonary inflammatory myofibroblastic tumour misdiagnosed as a round pneumonia
Samira Naime, Anjum Bandarkar, Gustavo Nino, Geovanny Perez
BMJ Case Reports.2018; : bcr-2017-224091. CrossRef

Case Study

A Rare Case of Aggressive Melanotic Schwannoma Occurred in Spinal Nerve of a 59-Year-Old Male: Sung-eun Choi, Yoon Jin Cha, Jisup Kim, Hyunseo Cha, Jayeong Seo, Sung-Uk Kuh, Sung-Jun Kim, Se Hoon Kim; J Pathol Transl Med. 2017;51(5):505-508. Published online April 4, 2017; DOI: https://doi.org/10.4132/jptm.2017.01.04

11,826 View
210 Download
18 Web of Science
15 Crossref

Abstract PDF

Melanotic schwannoma (MS) is a rare variant of nerve sheath neoplasm that shows ultrastructural and immunophenotypical features of Schwann cells but also has cytoplasmic melanosomes and is reactive for melanocytic markers as well. Unlike conventional schwannoma, which is totally benign, MS has an unpredictable prognosis and is thought to have low-malignant potential. Herein, we present a rare case of recurrent MS in lumbar spine of a 59-year-old male.

Citations

Citations to this article as recorded by

Case Report: Cutaneous melanocytic schwannoma with concomitant melanocytoma in a canine
Olwam H. Monakali, Nicolize O'Dell, Louise van der Weyden
Wellcome Open Research.2024; 8: 364. CrossRef
A Rare Case of Melanotic Schwannoma Occurred Intraosseous of Sacrum: A Literature Review
Xiaobo Yan, Keyi Wang, Nong Lin, Xin Huang, YanBiao Fu, Zhaoming Ye
Orthopaedic Surgery.2023; 15(2): 655. CrossRef
Sporadic spinal psammomatous malignant melanotic nerve sheath tumor: A case report and literature review
Giulio Bonomo, Alessandro Gans, Elio Mazzapicchi, Emanuele Rubiu, Paolo Alimonti, Marica Eoli, Rosina Paterra, Bianca Pollo, Guglielmo Iess, Francesco Restelli, Jacopo Falco, Francesco Acerbi, Marco Paolo Schiariti, Paolo Ferroli, Morgan Broggi
Frontiers in Oncology.2023;[Epub] CrossRef
Case Report: Cutaneous melanocytic schwannoma with concomitant melanocytoma in a canine
Olwam H. Monakali, Nicolize O'Dell, Louise van der Weyden
Wellcome Open Research.2023; 8: 364. CrossRef
Fine‐needle aspiration cytology of melanotic schwannoma in the submandibular gland
Yu‐Hua Huang, Ying‐Chou Lu, Hsuan‐Ying Huang, Chien‐Chin Chen
Diagnostic Cytopathology.2021; 49(1): 142. CrossRef
Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy
Jyoti Bajpai, Akhil Kapoor, Rakesh Jalali, Mrinal M Gounder
BMJ Case Reports.2021; 14(5): e240296. CrossRef
18F-FDG PET/CT imaging for aggressive melanotic schwannoma of the L3 spinal root
Xun-Ze Shen, Wei Wang, Zhou-Ye Luo
Medicine.2021; 100(8): e24803. CrossRef
Hemorrhagic spinal melanotic schwannoma presenting as acute chest pain: A case report and literature review
Dallas J. Soyland, Dylan R. Goehner, Kayla M. Hoerschgen, Troy D. Gust, Shawn M. Vuong
Surgical Neurology International.2021; 12: 164. CrossRef
Retroperitoneal Recurrence of Melanotic Schwannoma on 18F-FDG PET/CT
Xiangliu OuYang, Lichun Zheng, Xiaoming Zhang
Clinical Nuclear Medicine.2021; 46(12): 991. CrossRef
Schwannoma originating from the common iliac artery: a case report
Seung-Myoung Son, Chang Gok Woo
Journal of International Medical Research.2020; 48(2): 030006051984979. CrossRef
Intraosseous Melanotic Schwannoma in the Sacrum Mimicking Primary Bone Tumor
Yoshitaka Nagashima, Yusuke Nishimura, Kaoru Eguchi, Takayuki Awaya, Satoshi Yoshikawa, Shoichi Haimoto, Toshihiko Wakabayashi, Masahito Hara
NMC Case Report Journal.2020; 7(3): 107. CrossRef
Extramedullary melanotic schwannoma recurrence in the cervical vertebral arch: a case report and review of the literature
Zongbin Hou, Teng Shi, Guangrun Li, Lin Tian, Xinna Li, Xiaoyang Liu
Journal of International Medical Research.2020; 48(8): 030006052094791. CrossRef
Extramedullary malignant melanotic schwannoma of the spine: Case report and an up to date systematic review of the literature
Georgios Solomou, Adikarige Haritha Dulanka Silva, Adrianna Wong, Ute Pohl, Nikolaos Tzerakis
Annals of Medicine and Surgery.2020; 59: 217. CrossRef
Melanotic Schwannoma of the Vagina: A Report of a Very Rare Tumor and Review of the Literature
Kofi Effah, Stefan Seidl, Edith Gorges, Patrick Kafui Akakpo
Case Reports in Obstetrics and Gynecology.2019; 2019: 1. CrossRef
Melanotic Schwannomas Are Rarely Seen Pigmented Tumors with Unpredictable Prognosis and Challenging Diagnosis
Elif Keskin, Sumeyye Ekmekci, Ozgur Oztekin, Gulden Diniz
Case Reports in Pathology.2017; 2017: 1. CrossRef

Original Articles

Prognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy: Kyuho Lee, Kyoung-Bun Lee, Nam-Joon Yi, Kyung-Suk Suh, Ja-June Jang; J Pathol Transl Med. 2017;51(1):79-86. Published online December 25, 2016; DOI: https://doi.org/10.4132/jptm.2016.10.13

6,949 View
146 Download
4 Web of Science
3 Crossref

Abstract PDF

Background
Liver transplantation (LT) is the treatment of choice for hepatocellular carcinoma (HCC). The aim of this study was to investigate the recurrence rate of HCC after LT and prognostic factors for recurrence by comparing LT with non-transplanted resection. Methods: The participants were 338 patients who underwent LT between 1996 and 2012 at Seoul National University Hospital (LT group) and 520 HCC patients who underwent partial hepatectomy between 1995 and 2006 (control group, non-LT group). Results: In the LT group, 68 of 338 patients (19.8%) showed relapse, and the recurrence rate was lower than that in the non-LT group (64.9%, 357/520, p < .001). Stratification analysis by American Joint Committee on Cancer (AJCC) stage showed that the stage I-II LT group had a lower recurrence rate than the non-LT group. Univariate comparative analysis demonstrated that multiplicity of tumor, tumor size, gross type, Edmondson- Steiner (ES) nuclear grade, extent of tumor, angioinvasion, AJCC stage, Milan criteria, University of California at San Francisco criteria on explant pathology (all p < .001), positive expression of cytokeratin 19 (p = .002), and preoperative α-fetoprotein (AFP) (p < .001) were predictors of tumor recurrence. In multivariate analysis, LT, preoperative AFP, multiplicity of tumor, extent of tumor, size of tumor, and ES nuclear grade were independent prognostic factors. Conclusions: LT might have a protective effect against the late recurrence of stage I-II HCC compared to non-LT, and the prognostic factors for recurrence were similar to previously well-known prognostic factors for HCC.

Citations

Citations to this article as recorded by

Related Factors of Hepatocellular Carcinoma Recurrence Associated With Hyperglycemia After Liver Transplantation
Yujian Zheng, Qing Cai, Lishan Peng, Shibo Sun, Shaoping Wang, Jie Zhou
Transplantation Proceedings.2021; 53(1): 177. CrossRef
Oncological Outcomes of Hepatic Resection vs Transplantation for Localized Hepatocellular Carcinoma
A.T. Akcam, A.G. Saritas, A. Ulku, A. Rencuzogullari
Transplantation Proceedings.2019; 51(4): 1147. CrossRef
Clustering Asian Countries According to the Trend of liver cancer Mortality Rates: an Application of Growth Mixture Models
Maryam Salari, Anoshirvan Kazemnejad, Farid Zayeri
Iranian Red Crescent Medical Journal.2017;[Epub] CrossRef

The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence: Jee Soon Kim, Youn Soo Lee, Min Jung Jung, Yong Kil Hong; J Pathol Transl Med. 2016;50(6):419-425. Published online October 6, 2016; DOI: https://doi.org/10.4132/jptm.2016.06.30

7,433 View
228 Download
17 Web of Science
17 Crossref

Abstract PDF

Background
The 2004 World Health Organization classification introduced atypical pituitary adenoma (aPA), which was equivocally defined as invasion with increased mitotic activity that had a Ki-67 labeling index (LI) greater than 3%, and extensive p53 immunoreactivity. However, aPAs that exhibit all of these features are rare and the predictive value for recurrence in pituitary adenomas (PAs) remains uncertain. Thus, we sought to characterize pathological features of PAs that correlated with recurrence.
Methods
One hundred and sixty-seven cases of surgically resected PA or aPA were retrieved from 2011 to 2013 in Seoul St. Mary’s Hospital. Among them, 28 cases were confirmed to be recurrent, based on pathologic or radiologic examination. The pathologic characteristics including mitosis, invasion, Ki-67 LI and p53 immunoreactivity were analyzed in relation to recurrence.
Results
Analysis of the pathologic features indicated that only Ki-67 LI over 3% was significantly associated with tumor recurrence (p = .02). The cases with at least one pathologic feature showed significantly higher recurrence rates (p < .01). Analysis indicated that cases with two pathologic features, Ki-67 LI over 3% and extensive p53 immunoreactivity 20% or more, were significantly associated with tumor recurrence (p < .01).
Conclusions
Based on these results, PA tumor recurrence can be predicted by using mitosis, invasion, Ki-67 LI (3%), or extensive p53 immunoreactivity (≥ 20%). Assessment of these features is recommended for PA diagnosis for more accurate prediction of recurrence.

Citations

Citations to this article as recorded by

The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations
Roxana-Ioana Dumitriu-Stan, Iulia-Florentina Burcea, Valeria Nicoleta Nastase, Raluca Amalia Ceaușu, Anda Dumitrascu, Laurentiu Catalin Cocosila, Alexandra Bastian, Sabina Zurac, Marius Raica, Catalina Poiana
International Journal of Molecular Sciences.2023; 24(22): 16162. CrossRef
Ki-67/MIB-1 and Recurrence in Pituitary Adenoma
Kent Tadokoro, Colten Wolf, Joseph Toth, Cara Joyce, Meharvan Singh, Anand Germanwala, Chirag Patel
Journal of Neurological Surgery Part B: Skull Base.2022; 83(S 02): e580. CrossRef
Association of PTTG1 expression with invasiveness of non-functioning pituitary adenomas
Su Jung Kum, Hye Won Lee, Soon Gu Kim, Hyungsik Park, Ilseon Hwang, Sang Pyo Kim
Journal of Pathology and Translational Medicine.2022; 56(1): 22. CrossRef
A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years
Yu Zhang, Yuqi Luo, Xin Kong, Tao Wan, Yunling Long, Jun Ma
Frontiers in Neurology.2022;[Epub] CrossRef
Endoscopic Endonasal Pituitary Surgery For Nonfunctioning Pituitary Adenomas: Long-Term Outcomes and Management of Recurrent Tumors
Anne-Laure Bernat, Pénélope Troude, Stefano Maria Priola, Ahmad Elsawy, Faisal Farrash, Ozgur Mete, Shereen Ezzat, Sylvia L. Asa, John De Almeida, Allan Vescan, Eric Monteiro, Joao Paulo Almeida, Gelareh Mohammed Zadeh, Fred Gentili
World Neurosurgery.2021; 146: e341. CrossRef
A Nomogram for Preoperatively Predicting the Ki-67 Index of a Pituitary Tumor: A Retrospective Cohort Study
Xiangming Cai, Junhao Zhu, Jin Yang, Chao Tang, Feng Yuan, Zixiang Cong, Chiyuan Ma
Frontiers in Oncology.2021;[Epub] CrossRef
Comparative Proteomic Study Shows the Expression of Hint-1 in Pituitary Adenomas
Carolina Carrillo-Najar, Daniel Rembao-Bojórquez, Martha L. Tena-Suck, Sergio Zavala-Vega, Noemí Gelista-Herrera, Miguel A. Ramos-Peek, Juan L. Gómez-Amador, Febe Cazares-Raga, Fidel de la Cruz Hernández-Hernández, Alma Ortiz-Plata
Diagnostics.2021; 11(2): 330. CrossRef
Prediction of recurrence in solid nonfunctioning pituitary macroadenomas: additional benefits of diffusion-weighted MR imaging
Ching-Chung Ko, Tai-Yuan Chen, Sher-Wei Lim, Yu-Ting Kuo, Te-Chang Wu, Jeon-Hor Chen
Journal of Neurosurgery.2020; 132(2): 351. CrossRef
Pituitary tumors: epidemiology and clinical presentation spectrum
Marta Araujo-Castro, Víctor Rodríguez Berrocal, Eider Pascual-Corrales
Hormones.2020; 19(2): 145. CrossRef
Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature
E. Guadagno, E. D’Avella, P. Cappabianca, A. Colao, M. Del Basso De Caro
Journal of Endocrinological Investigation.2020; 43(10): 1429. CrossRef
Study of Simple Immunohistochemical Cytocolorimetric Assay Application for More Accurate Assessment of Prognosis in Patients with Pituitary Adenomas
Pavel V. Nikitin, Marina V. Ryzhova, Lyudmila V. Shishkina, Svetlana V. Shugay, Irina V. Zubova
World Neurosurgery.2019; 122: e1047. CrossRef
The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas
Rovshan Hasanov, Berna İmge Aydoğan, Saba Kiremitçi, Esra Erden, Sevim Güllü
Endocrine Pathology.2019; 30(1): 49. CrossRef
Residual Tumor Confers a 10-Fold Increased Risk of Regrowth in Clinically Nonfunctioning Pituitary Tumors
Jelena Maletkovic, Asmaa Dabbagh, Dongyun Zhang, Abdul Zahid, Marvin Bergsneider, Marilene B Wang, Michael Linetsky, Noriko Salamon, William H Yong, Harry V Vinters, Anthony P Heaney
Journal of the Endocrine Society.2019; 3(10): 1931. CrossRef
Atypical pituitary adenoma: a clinicopathologic case series
Martin J. Rutkowski, Ryan M. Alward, Rebecca Chen, Jeffrey Wagner, Arman Jahangiri, Derek G. Southwell, Sandeep Kunwar, Lewis Blevins, Han Lee, Manish K. Aghi
Journal of Neurosurgery.2018; 128(4): 1058. CrossRef
Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients
Julie Lelotte, Anne Mourin, Edward Fomekong, Alex Michotte, Christian Raftopoulos, Dominique Maiter
European Journal of Endocrinology.2018; 178(3): 237. CrossRef
Letter to the Editor. Atypical pituitary adenoma
Lauren E. Rotman, T. Brooks Vaughan, James R. Hackney, Kristen O. Riley
Journal of Neurosurgery.2018; 129(6): 1657. CrossRef
Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies
Anna Angelousi, Georgios K Dimitriadis, Georgios Zografos, Svenja Nölting, Gregory Kaltsas, Ashley Grossman
Endocrine-Related Cancer.2017; 24(6): R239. CrossRef

Extrapulmonary Lymphangioleiomyoma: Clinicopathological Analysis of 4 Cases: Dae Hyun Song, In Ho Choi, Sang Yun Ha, Kang Min Han, Jae Jun Lee, Min Eui Hong, Yoon-La Choi, Kee-Taek Jang, Sang Yong Song, Chin A Yi, Joungho Han; Korean J Pathol. 2014;48(3):188-192. Published online June 26, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.3.188

7,739 View
58 Download
9 Crossref

Abstract PDF

Background

Lymphangioleiomyomatosis (LAM) is a slowly progressive neoplastic disease that predominantly affects females. Usually, LAM affects the lung; it can also affect extrapulmonary sites, such as the mediastinum, the retroperitoneum, or the lymph nodes, although these locations are rare. A localized form of LAM can manifest as extrapulmonary lesions; this form is referred to as extrapulmonary lymphangioleiomyoma (E-LAM). Due to the rare occurrence of E-LAM and its variable, atypical location, E-LAM is often difficult to diagnose. Herein, we report the clinicopathological information from four E-LAM cases, and also review previous articles investigating this disease.

Methods

Four patients with E-LAM were identified at the Samsung Medical Center (Seoul, Korea) from 1995 to 2012. All E-LAM lesions underwent surgical excision.

Results

All patients were females within the age range of 43 to 47 years. Two patients had para-aortic retroperitoneal masses, while the other two patients had pelvic lesions; two out of the four patients also had accompanying pulmonary LAM. In addition, no patient displayed any evidence of tuberous sclerosis. Histologically, two patients exhibited nuclear atypism with cytologic degeneration.

Conclusions

E-LAM should be considered in the differential diagnosis of patients presenting with pelvic or para-aortic masses. We also conclude that further clinical and pathological evaluation is needed in patients with E-LAM and nuclear atypism.

Citations

Citations to this article as recorded by

Lymphangioleiomyomatosis with Tuberous Sclerosis Complex—A Case Study
Aleksandra Marciniak, Jolanta Nawrocka-Rutkowska, Agnieszka Brodowska, Andrzej Starczewski, Iwona Szydłowska
Journal of Personalized Medicine.2023; 13(11): 1598. CrossRef
A case of lymphangioleiomyomatosis with endometrial cancer diagnosed by retroperitoneoscopic para-aortic lymph node dissection
Aiko Ogasawara, Shogo Yamaguchi, Hiroaki Inui, Mieko Hanaoka, Daisuke Shintani, Sho Sato, Masanori Yasuda, Akira Yabuno
JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY.2022; 38(1): 158. CrossRef
Primary retroperitoneal PEComa: an incidental finding
Bárbara Monteiro Marinho, António Gâmboa Canha, Donzília Sousa Silva, José Davide Pinto Silva
BMJ Case Reports.2022; 15(11): e250466. CrossRef
Imaging Findings of Thoracic Lymphatic Abnormalities
Jingshuo (Derek) Sun, Thomas Shum, Fardad Behzadi, Mark M. Hammer
RadioGraphics.2022; 42(5): 1265. CrossRef
Extrapulmonary uterine lymphangioleiomyomatosis (LAM) and dysfunctional uterine bleeding: the first presentation of LAM in a tuberous sclerosis complex patient
Lucy Grant, Saliya Chipwete, San Soo Hoo, Anjali Bhatnagar
BMJ Case Reports.2019; 12(2): e226358. CrossRef
Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia
Takashi Ogura, Nagio Takigawa, Keisuke Tomii, Kazuma Kishi, Yoshikazu Inoue, Eiki Ichihara, Sakae Homma, Kazuhisa Takahashi, Hiroaki Akamatsu, Satoshi Ikeda, Naohiko Inase, Tae Iwasawa, Yuichiro Ohe, Hiromitsu Ohta, Hiroshi Onishi, Isamu Okamoto, Kazumasa
Respiratory Investigation.2019; 57(6): 512. CrossRef
Incidental lymphangioleiomyomatosis in the lymph nodes of gynecologic surgical specimens
Ikumi Kuno, Hiroshi Yoshida, Hanako Shimizu, Takashi Uehara, Masaya Uno, Mitsuya Ishikawa, Tomoyasu Kato
European Journal of Obstetrics & Gynecology and Reproductive Biology.2018; 231: 93. CrossRef
Solitary extrapulmonary lymphangioleiomyomatosis of the liver: A case report and literature review
Weiwei Fu, Yujun Li, Hong Li, Ping Yang, Xiaoming Xing
Experimental and Therapeutic Medicine.2016; 12(3): 1499. CrossRef
Incidental Pelvic and Para-aortic Lymph Node Lymphangioleiomyomatosis Detected During Surgical Staging of Pelvic Cancer in Women Without Symptomatic Pulmonary Lymphangioleiomyomatosis or Tuberous Sclerosis Complex
Joseph T. Rabban, Brandie Firetag, Ankur R. Sangoi, Miriam D. Post, Charles J. Zaloudek
American Journal of Surgical Pathology.2015; 39(8): 1015. CrossRef

Tumor Sprouting in Papillary Thyroid Carcinoma Is Correlated with Lymph Node Metastasis and Recurrence: Eunjung Lee, Wonkyung Jung, Jeong-Soo Woo, Jae Bok Lee, Bong Kyung Shin, Han Kyeom Kim, Aeree Kim, Baek-hui Kim; Korean J Pathol. 2014;48(2):117-125. Published online April 28, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.2.117

9,783 View
62 Download
6 Crossref

Abstract PDF

Background

Identification of poor prognostic factors in papillary thyroid carcinoma (PTC) patients is important for the patients' care and follow-up. We can sometimes see small tumor clusters without desmoplasia and no evidence of lymphatic emboli around the main tumor mass of PTC. We termed this form of tumor clustering, 'tumor sprouting,' and determined whether these tumors correlate with lymphovascular invasion, lymph node metastasis, and recurrence.

Methods

We analyzed a total of 204 cases of papillary thyroid macrocarcinoma. Number, size and distance from the main tumor of the tumor sprouting were observed and analyzed with clinicopathologic characteristics.

Results

Tumor sprouting was observed in 101 patients. Presence of tumor sprouting was significantly associated with positive resection margin (p=.002), lymphovascular invasion (p=.001), lymph node metastasis (p<.001), and recurrence (p=.004). Univariate analysis of recurrence-free survival revealed that tumor multiplicity (p=.037), positive resection margin (p=.007), lymphovascular invasion (p=.004), lymph node metastasis (p<.001), and tumor sprouting (p=.004) were poor prognostic factors. In multivariate analysis, positive resection margin was an independent poor prognostic factor of recurrence.

Conclusions

In conclusion, tumor sprouting is significantly correlated with lymph node metastasis and recurrence. Evaluation of tumor sprouting in PTC patients could be helpful in predicting tumor recurrence or lymph node metastasis.

Citations

Citations to this article as recorded by

Significance of Lymphovascular Invasion as a Prognostic Factor in Patients with Papillary Thyroid Cancer: a Systematic Review and Meta-Analysis
Ho-Ryun Won, Bon Seok Koo
International Journal of Thyroidology.2023; 16(2): 157. CrossRef
Peripheral Versus Intraparenchymal Papillary Thyroid Microcarcinoma: Different Morphologies and PD-L1 Expression
Bozidar Kovacevic, Dragana Vucevic, Snezana Cerovic, Catarina Eloy
Head and Neck Pathology.2022; 16(1): 200. CrossRef
Lymphovascular invasion and risk of recurrence in papillary thyroid carcinoma
Katy Wagner, Earl Abraham, Bryan Tran, David Roshan, James Wykes, Peter Campbell, Ardalan Ebrahimi
ANZ Journal of Surgery.2020; 90(9): 1727. CrossRef
The Predictors of Multicentricity in Well-Differentiated Thyroid Cancer
Mohamed Hegazi, Waleed El Nahas, Mohamed Elmetwally, Amr Hassan, Waleed Gado , Islam Abdou, Ahmed Senbel, Mohamed Samir Abou-Sheishaa
Journal of Analytical Oncology.2018; 7(4): 65. CrossRef
Prognostic impact of vascular invasion in differentiated thyroid carcinoma: a systematic review and meta-analysis
Huy Gia Vuong, Tetsuo Kondo, Uyen N P Duong, Thong Quang Pham, Naoki Oishi, Kunio Mochizuki, Tadao Nakazawa, Lewis Hassell, Ryohei Katoh
European Journal of Endocrinology.2017; 177(2): 207. CrossRef
Detection of Tumor Multifocality Is Important for Prediction of Tumor Recurrence in Papillary Thyroid Microcarcinoma: A Retrospective Study and Meta-Analysis
Jung-Soo Pyo, Jin Hee Sohn, Guhyun Kang
Journal of Pathology and Translational Medicine.2016; 50(4): 278. CrossRef

Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma: Jiyeon Hyeon, Soomin Ahn, Jae Jun Lee, Dae Hyun Song, Cheol-Keun Park; Korean J Pathol. 2013;47(2):130-136. Published online April 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.130

7,373 View
53 Download
18 Crossref

Abstract PDF

Background

BCL9 enhances β-catenin-mediated transcriptional activity regardless of the mutational status of the Wnt signaling components and increases the cell proliferation, migration, invasion, and metastatic potential of tumor cells. The goal of this study was to elucidate the prognostic significance of BCL9 protein expression in hepatocellular carcinoma (HCC) patients.

Methods

We evaluated BCL9 protein expression by immunohistochemistry in tumor tissue from 288 primary HCC patients who underwent curative hepatectomy. The impact of BCL9 expression on the survival of the patients was analyzed. The median follow-up period was 97.1 months.

Results

Nuclear BCL9 protein expression was observed in 74 (25.7%) of the 288 HCCs. BCL9 expression was significantly associated with younger age (p=0.038), higher Edmondson grade (p=0.001), microvascular invasion (p=0.013), and intrahepatic metastasis (p=0.017). Based on univariate analyses, BCL9 expression showed an unfavorable influence on both disease-free survival (DFS, p=0.012) and disease-specific survival (DSS, p=0.032). Multivariate analyses revealed that higher Barcelona Clinic Liver Cancer stage was an independent predictor of both shorter DFS (p<0.001) and shorter DSS (p<0.001). BCL9 expression tended to be an independent predictor of shorter DFS (p=0.078).

Conclusions

BCL9 protein expression might be a marker of shorter DFS in HCC patients after curative hepatectomy.

Citations

Citations to this article as recorded by

The Wnt-dependent and Wnt-independent functions of BCL9 in development, tumorigenesis, and immunity: Implications in therapeutic opportunities
Minjie Wu, Heng Dong, Chao Xu, Mengqing Sun, Haojin Gao, Fangtian Bu, Jianxiang Chen
Genes & Diseases.2024; 11(2): 701. CrossRef
The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients
Eman Abd El Razek Abbas, Ahmed Barakat Barakat, Mohamed Hassany, Samar Samir Youssef
Journal of Genetic Engineering and Biotechnology.2022; 20(1): 4. CrossRef
Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma
Kwang-Hoon Chun
Pharmaceutics.2022; 14(7): 1380. CrossRef
Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells
Roland Kotolloshi, Mieczyslaw Gajda, Marc-Oliver Grimm, Daniel Steinbach
International Journal of Molecular Sciences.2022; 23(10): 5319. CrossRef
Bcl9 Depletion Modulates Endothelial Cell in Tumor Immune Microenvironment in Colorectal Cancer Tumor
Zhuang Wei, Mei Feng, Zhongen Wu, Shuru Shen, Di Zhu
Frontiers in Oncology.2021;[Epub] CrossRef
Wnt Signaling Pathway Is among the Drivers of Liver Metastasis
Ivana Samaržija
Livers.2021; 1(4): 180. CrossRef
Nuclear Expression of Pygo2 Correlates with Poorly Differentiated State Involving c-Myc, PCNA and Bcl9 in Myanmar Hepatocellular Carcinoma
Myo Win Htun, Yasuaki Shibata, Kyaw Soe, Takehiko Koji
ACTA HISTOCHEMICA ET CYTOCHEMICA.2021; 54(6): 195. CrossRef
Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma
Nicole Huge, Maria Sandbothe, Anna K. Schröder, Amelie Stalke, Marlies Eilers, Vera Schäffer, Brigitte Schlegelberger, Thomas Illig, Beate Vajen, Britta Skawran
Hepatology International.2020; 14(3): 373. CrossRef
Structure and function of Pygo in organ development dependent and independent Wnt signalling
Yan Shi, Xiushan Wu, Shuoji Zhu, Huanlei Huang, Jian Zhuang, Haiyun Yuan, Wuzhou Yuan, Ping Zhu
Biochemical Society Transactions.2020; 48(4): 1781. CrossRef
BCL9/BCL9L in hepatocellular carcinoma: will it or Wnt it be the next therapeutic target?
Akshata Moghe, Satdarshan P. Monga
Hepatology International.2020; 14(4): 460. CrossRef
Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer
David M. Gay, Rachel A. Ridgway, Miryam Müller, Michael C. Hodder, Ann Hedley, William Clark, Joshua D. Leach, Rene Jackstadt, Colin Nixon, David J. Huels, Andrew D. Campbell, Thomas G. Bird, Owen J. Sansom
Nature Communications.2019;[Epub] CrossRef
Immunohistochemical Mapping of Bcl9 Using Two Antibodies that Recognize Different Epitopes Is Useful to Characterize Juvenile Development of Hepatocellular Carcinoma in Myanmar
Myat Thu Soe, Yasuaki Shibata, Myo Win Htun, Kuniko Abe, Kyaw Soe, Nay Win Than, Thann Lwin, Myat Phone Kyaw, Takehiko Koji
ACTA HISTOCHEMICA ET CYTOCHEMICA.2019; 52(1): 9. CrossRef
Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells
Jing Wang, Mingjun Zheng, Liancheng Zhu, Lu Deng, Xiao Li, Linging Gao, Caixia Wang, Huimin Wang, Juanjuan Liu, Bei Lin
Cancer Cell International.2019;[Epub] CrossRef
SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction
Rong Fan, HaiYan He, Wang Yao, YanFeng Zhu, XunJie Zhou, MingTai Gui, Jing Lu, Hao Xi, ZhongLong Deng, Min Fan
DNA and Cell Biology.2018; 37(2): 126. CrossRef
Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma
Wei Xu, Wang Zhou, Mo Cheng, Jing Wang, Zhian Liu, Shaohui He, Xiangji Luo, Wending Huang, Tianrui Chen, Wangjun Yan, Jianru Xiao
Scientific Reports.2017;[Epub] CrossRef
Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA
Mohamed Abd El-Fattah
Indian Journal of Gastroenterology.2017; 36(2): 117. CrossRef
miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models
Xuan Liu, Qing Ji, Chengcheng Zhang, Xiaowei Liu, Yanna Liu, Ningning Liu, Hua Sui, Lihong Zhou, Songpo Wang, Qi Li
Scientific Reports.2017;[Epub] CrossRef
BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression
XIAO-HUI LING, ZHI-YUN CHEN, HONG-WEI LUO, ZE-ZHEN LIU, YING-KE LIANG, GUAN-XING CHEN, FU-NENG JIANG, WEI-DE ZHONG
Oncology Letters.2016; 11(3): 2001. CrossRef

Case Report

Tumor Budding and Recurrence in Submucosal Invasive Colorectal Cancers of Favorable Histology: Case Reports of Two Early Colorectal Cancers with Advanced Recurrences: Heae Surng Park, Hee Jin Chang, Ji Won Park, Byung Chang Kim, Dae Kyung Sohn, Chang Won Hong, Ji-Yeon Baek, Sun Young Kim, Hyo Seong Choi, Jae Hwan Oh; Korean J Pathol. 2012;46(3):272-277. Published online June 22, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.3.272

7,203 View
49 Download
3 Crossref

Abstract PDF

Complete resection of submucosal invasive colorectal cancer (SICC) showing favorable histology is regarded as curative. We report on two cases of SICC showing recurrence within 5 years despite complete resection. The first patient was a 68-year-old woman with well differentiated rectal adenocarcinoma invading the superficial submucosa, which recurred after 4.7 years. The second patient was a 53-year-old man with pT1N0 moderately differentiated colonic adenocarcinoma. He developed widespread tumor recurrence after 3.9 years. Retrospective pathologic review of the original tumors showed multiple foci of tumor budding at the invasive front. Immunohistochemical staining for D2-40 of deeper levels of the paraffin blocks showed rare foci of small lymphatic invasion. Tumor budding at the invasive front may be an important indicator for SICC aggressiveness or may reflect early lymphatic invasion. More aggressive pathologic examination and follow-up is required for patients with SICC showing tumor budding, even in the absence of unfavorable histologic findings.

Citations

Citations to this article as recorded by

Estudio de factores histológicos predictivos de metástasis ganglionar locorregional en adenocarcinoma colorrectal mínimamente invasivo pT1
Isidro Machado, Miriam Valera-Alberni, Fernando Martínez de Juan, José A. López-Guerrero, Alfonso García Fadrique, Julia Cruz, Carmen Martínez Lapiedra, Fernanda Maia de Alcantara, Ricardo Yaya, Jorge Campos, Carlos Fernández-Martos, Rafael Estevan
Gastroenterología y Hepatología.2016; 39(1): 1. CrossRef
Histological factors predicting loco-regional lymph node metastasis in early invasive colorectal adenocarcinoma pT1
Isidro Machado, Miriam Valera-Alberni, Fernando Martínez de Juan, José A. López-Guerrero, Alfonso García Fadrique, Julia Cruz, Carmen Martínez Lapiedra, Fernanda Maia de Alcantara, Ricardo Yaya, Jorge Campos, Carlos Fernández-Martos, Rafael Estevan
Gastroenterología y Hepatología (English Edition).2016; 39(1): 1. CrossRef
Tumor budding in the clinical management of colon and rectal cancer
Viktor H Koelzer, Inti Zlobec, Alessandro Lugli
Colorectal Cancer.2014; 3(4): 387. CrossRef

Original Articles

Expression of Hepatocyte Growth Factor/c-met by RT-PCR in Meningiomas.: Na Rae Kim, Yang Seok Chae, Weon Jeong Lim, Seong Jin Cho; Korean J Pathol. 2011;45(5):463-468.; DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.5.463

3,042 View
25 Download

Abstract PDF: BACKGROUND
Hepatocyte growth factor (HGF) is a potent mitogenic cytokine. C-met protein, which is known to be the HGF receptor has transmembrane tyrosine kinase activity and is encoded by the c-met oncogene. The HGF/c-met signaling pathway may play various roles in the carcinogenesis of various organs.
METHODS
We examined HGF and c-met mRNA expression by utilizing reverse transcription polymerase chain reaction on 40 surgically resected intracranial meningiomas (25 benign, 10 atypical, and 5 anaplastic cases).
RESULTS
An HGF overexpression was detected in 28%, 50%, and 80% of the benign, atypical and anaplastic meningiomas, respectively; a high expression of HGF or the coexpression of HGF/c-met was detected in the high grade meningiomas (the atypical and anaplastic cases, p=0.046, p=0.014). An HGF expression was statistically significant in the recurrent meningiomas (p=0.003), and HGF expression was significantly lower than c-met mRNA expression in benign meningiomas (p=0.034).
CONCLUSIONS
There was no correlation between histologic subtypes and HGF/c-met expression. Determination of HGF expression can be used as a molecular predictor for recurrence of meningioimas. These results suggest that HGF and c-met expression in meningiomas may be associated with anaplastic progression.

Clinical Outcome of Surgically Resected Pancreatic Intraductal Papillary Mucinous Neoplasm According to the Marginal Status: A Single Center Experience.: Sun A Kim, Eunsil Yu, Song Cheol Kim, Jihun Kim; Korean J Pathol. 2010;44(4):410-419.; DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.4.410

3,300 View
15 Download
3 Crossref

Abstract PDF

BACKGROUND
Surgical resection is the treatment of choice of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. However, the benefit of clearing resection margin is still controversial.
METHODS
We reviewed 281 surgically resected cases of IPMN. The recurrences were compared according to the histologic grade (benign or borderline IPMN, malignant noninvasive IPMN, invasive carcinoma) and size (pancreatic intraepithelial neoplasia, PanIN, less than 0.5 cm in the long axis; and IPMN, greater than or equal to 0.5 cm) of the residual lesions at the resection margin.
RESULTS
Sixty cases (21.4%) were invasive carcinoma, and 221 (78.6%) noninvasive cases included 87 (31.0%) benign, 107 (38.1%) borderline and 11 (3.9%) malignant noninvasive IPMN cases. In noninvasive IPMN, increased recurrence in patients with five or more years of follow-up was only related to the involvement of resection margin by severe dysplasia. The recurrence of invasive carcinoma was high (27.3%) even when the resection margin was clear, and was not related to the grade or size of residual tumors at the resection margin.
CONCLUSIONS
Invasiveness is a strong risk factor for recurrence in IPMN regardless of the status of the resection margin. However, in noninvasive IPMN, histologic grading of residual lesions at the resection margin predicts local recurrence.

Citations

Citations to this article as recorded by

Systematic review of challenging issues in pathology of intraductal papillary mucinous neoplasms
Laura D. Wood, N. Volkan Adsay, Olca Basturk, Lodewijk A.A. Brosens, Noriyoshi Fukushima, Seung-Mo Hong, Sung-Joo Kim, Jae W. Lee, Claudio Luchini, Michaël Noë, Martha B. Pitman, Aldo Scarpa, Aatur D. Singhi, Mariko Tanaka, Toru Furukawa
Pancreatology.2023; 23(7): 878. CrossRef
The Use of Intraoperative Frozen Sections in Guiding the Extent of Pancreatic Resections for Intraductal Papillary Mucinous Neoplasms
Zhikai Chi, Deepti Dhall, Richard Mertens
Pancreas.2022; 51(1): 63. CrossRef
Recurrence of non-invasive intraductal papillary municious neoplasm seven years following total pancreatectomy
Nayima M. Clermont Dejean, Sinziana Dumitra, Jeffrey S. Barkun
International Journal of Surgery Case Reports.2013; 4(9): 789. CrossRef

Case Report

Recurred Angiomyofibroblastoma of the Vulva: Report of a case.: Do Youn Park, Ji Yeon Kim, OK Hyeon Kim, Hwa Sun Lee, Mee Young Sol, Kang Suek Suh, Sun Kyung Lee; Korean J Pathol. 1996;30(10):947-950.

1,734 View
21 Download

Abstract PDF: Angiomyofibroblastoma is a rare, benign mesenchymal tumor of the vulva. Since it was described in 1992 by Fletcher, 15 cases have been reported in literature. We recently experienced a recurred angiomyofibroblastoma of the vulva. A 45-year-old woman was presented initially in 1991 with a mass of labium major and local excision of tumor mass had been performed. A histologic diagnosis was made of angiomyxoma, but this diagnosis was revised to angiomyofibroblastoma by the authors. The recurred mass was well circumscribed, measuring 2.5x1.6x1.5cm in dimensions. Microscopically the tumor was characterized by high cellularity, numerous blood vessels(which lack prominent hyalinization), and plump stromal cells. Immunohistochemically, the stromal cells were reactive for vimentin and desmin, but not alpha-smooth muscle actin, or S-100 protein. We thought that this case was a recurred angiomyofibrblastoma of the vulva due to incomplete surgical excision.

Original Articles

p53 Expression and Ki-67 Labeling Index in Brain Tumor with Special Reference to Tumor and Histologic Grade.: Duck Hwan Kim, Yeon Lim Suh, Dong Ik Shin, Hyung Jin Shin, Jong Hyun Kim; Korean J Pathol. 1998;32(2):81-87.

2,947 View
80 Download

Abstract PDF: Mutation in the p53 suppressor gene is the most common genetic alteration found in human cancers including primary brain tumors. Ki-67 labeling index(LI) is known to be a marker of proliferating activity. The purpose of this study was to verify whether an immunohistochemical expression of p53 antibody and Ki-67 LI could be related to different clinicopathologic parameters including histologic grade, size, invasiveness and recurrence of the brain tumors. Materials were based on the 147 surgically resected brain tumors during the last two years. Of the 147 brain tumors, there were 35 astrocytic tumors, 35 meningiomas, 10 oligodendrogliomas, 7 craniopharyngiomas, 5 dysembryoplastic neuroepithelial tumors, 4 medulloblastomas, 5 ependymomas, 23 pituitary adenomas, 9 schwannomas, and 14 other brain tumors. The p53 expression and Ki-67 LI were higher in malignant brain tumors including astrocytic tumors, medulloblastoma, PNET and gliosarcoma. The p53 positivity was correlated with histologic grades and tumor recurrence. The brain tumors with a high Ki-67 LI(>6%) also showed a close relationship to a higher histologic grading, radiological invasiveness and recurrence. There was no evident correlation with the age and tumor size with p53 expression and Ki-67 LI. These results suggest that p53 overexpression and high proliferation potential of the tumor cells are associated with the higher histologic grade and aggressive clinical course in the central nervous system tumors.

The Clinicopathologic Analysis of Kikuchi's Lymphadenitis.: Jung Woo Choi, Ji Hye Lee, Ju Han Lee, Yang Seok Chae, Insun Kim; Korean J Pathol. 2004;38(5):289-294.

1,577 View
20 Download

Abstract PDF: BACKGROUND
Kikuchi's disease has been known as a self-limiting lymphadenitis mostly affecting the cervical lymph nodes of young women.
METHODS
We retrospectively reviewed the clinical data of 77 cases of Kikuchi's lymphadenitis from 1996 to 2003 at Korea University Medical Center.
RESULTS
Histologically, 69 available cases were classified into three types: proliferative (60.8%), necrotizing (33.3%), and xanthomatous type (5.7%). These three types differed in terms of their clinical features, showing tenderness most predominantly in the necrotizing type. In spite of the insufficient numbers of cases, the data on the duration of the disease well correlated with the possible progression of the three histologic types (Kikuch's disease begins as proliferative type, then progress into necrotizing type and finally resolves into xanthomatous type). During the ten-month period of the mean follow-up, the recurrence rate was 7.0%. Three and two patients developed into pulmonary tuberculosis and systemic lupus erythematosus, respectively, but there were no prognostic differences among the three types.
CONCLUSIONS
Our results confirmed that Kikuchi's lymphadenitis is a self-limiting necrotizing lymphadenitis with a low rate of recurrence. Here, we suggest that the classification of histologic types have some meanings because of their differences in certain clinical aspects and possible sequential disease progression.

First
Prev
Page of 2
Next
Last

Search